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AbstrAct
Objective Women with a history of gestational diabetes 
mellitus (GDM) have an exceptionally high risk for type 
2 diabetes (T2D). Yet, little is known about genetic 
determinants for T2D in this population. We examined the 
association of a genetic risk score (GRS) with risk of T2D 
in two independent populations of women with a history of 
GDM and how this association might be modified by non- 
genetic determinants for T2D.
Research design and methods This cohort study 
included 2434 white women with a history of GDM from 
the Nurses’ Health Study II (NHSII, n=1884) and the 
Danish National Birth Cohort (DNBC, n=550). A GRS for 
T2D was calculated using 59 candidate single nucleotide 
polymorphisms for T2D identified from genome- wide 
association studies in European populations. An alternate 
healthy eating index (AHEI) score was derived to reflect 
dietary quality after the pregnancy affected by GDM.
Results Women on average were followed for 21 years 
in NHSII and 13 years in DNBC, during which 446 (23.7%) 
and 155 (28.2%) developed T2D, respectively. The GRS 
was generally positively associated with T2D risk in both 
cohorts. In the pooled analysis, the relative risks (RRs) for 
increasing quartiles of GRS were 1.00, 0.97, 1.25 and 1.19 
(p trend=0.02). In both cohorts, the association appeared 
to be stronger among women with poorer (AHEI <median) 
than better dietary quality (AHEI ≥median), although the 
interaction was not significant. For example, in NHSII, 
the RRs across increasing quartiles of GRS were 1.00, 
0.99, 1.51 and 1.29 (p trend=0.06) among women with 
poorer dietary quality and 1.00, 0.83, 0.81 and 0.94 (p 
trend=0.79) among women with better dietary quality (p 
interaction=0.11).
Conclusions Among white women with a history of GDM, 
higher GRS for T2D was associated with an increased risk 
of T2D.
InTROduCTIOn
Gestational diabetes mellitus (GDM) is a 
common pregnancy complication affecting 
6%–15% of pregnancies across world regions.1 
Although the condition resolves after delivery 
in most cases, women with a history of GDM 
have a more than sevenfold increased risk of 
developing type 2 diabetes (T2D) compared 
with women with a normoglycemic preg-
nancy2; 14%–41% of women with a history 
of GDM develop T2D within 10 years of the 
pregnancy affected by GDM,3–5 and the cumu-
lative incidence of T2D continues to increase 
afterwards.3 5 As such, women with a history 
of GDM constitute a high- risk population for 
T2D, and the period after a pregnancy compli-
cated by GDM presents a unique window of 
significance of this study
What is already known about this subject?
 ► Genetic risk factors have been associated with type 
2 diabetes (T2D) risk in the general population.
What are the new findings?
 ► In this study based on two independent population of 
white women with a history of gestational diabetes 
mellitus (GDM) followed over long period, the genetic 
risk score was positively associated with the risk of 
T2D.
 ► The excess risk appeared to be mitigated by better 
dietary quality after the pregnancy affected by GDM.
How might these results change the focus of 
research or clinical practice?
 ► These findings advance our understanding of the 
genetic risk for T2D among women with a history of 
GDM. It also offers further evidence to support public 
health efforts of encouraging a healthful diet to pre-
vent T2D among this high- risk population—women 
with a history of GDM.
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opportunity for prevention. To inform such prevention 
strategies, understanding the genetic and environmental 
factors associated with T2D among women with a history 
of GDM is critical.
Individual single nucleotide polymorphisms (SNPs) 
and genetic risk scores (GRSs) capturing the cumula-
tive risk conferred by these SNPs have been associated 
with T2D risk in the general population.6 7 However, as 
women with a history of GDM already have an elevated 
baseline genetic risk for T2D compared with the general 
population,8 9 the role genetic factors play in the develop-
ment of T2D among women with a history of GDM may 
differ from that in the general population. So far, few 
studies have examined the association of genetic factors 
including individual SNPs and GRSs with the risk of T2D 
among women with a history of GDM10–13; inferences 
from these studies are hindered by small numbers of T2D 
cases (n<150), and relatively short follow- up periods (<5 
years). Lastly, no study has examined how non- genetic 
factors may modify the genetic risk for T2D among 
women with a history of GDM, although such knowledge 
may guide targeted T2D prevention among this high- risk 
population.
In the present study, we examined the association of 
a GRS for T2D with the risk of T2D among two inde-
pendent population of women with a history of GDM 
followed over long period. We further investigated how 
this association might be modified by non- genetic factors 
of T2D.
MaTeRIals and MeTHOds
study population
The current study included women from the Diabetes 
& Women’s Health (DWH) Study, a prospective cohort 
study of 4457 women with a history of GDM who were 
enrolled from two prospective cohorts, the Nurses’ 
Health Study II (NHSII) and the Danish National Birth 
Cohort (DNBC).14 All participants of the DWH Study 
provided written informed consent.
A total of 3667 NHSII participants who developed 
GDM were included in the DWH Study. The NHSII is 
an ongoing prospective US cohort study that enrolled 
116 430 female registered nurses aged 25- to 42- year old in 
1989.15 Questionnaires were administered at enrollment 
and every other year thereafter. Women who developed 
GDM were primarily identified from the main biennial 
NHSII questionnaire, where women reported physician’s 
diagnoses of GDM up until 2001. Additional GDM cases 
were identified in the 2009 pregnancy questionnaire, 
which recorded about women’s recall of physicians’ diag-
noses of GDM in all previous pregnancies. The pregnancy 
during which GDM was diagnosed was referred to as the 
index pregnancy. Self- reported GDM status in the bien-
nial questionnaire was previously validated using medical 
records with confirmation among 94% of the cases.16 
Women who participated in the DWH Study were largely 
comparable to women with GDM in the overall NHSII.14 
The NHSII part of the DWH Study was approved by the 
institutional review boards of Brigham and Women’s 
Hospital and the Harvard T. H. Chan School of Public 
Health.
A total of 790 DNBC participants who developed GDM 
during a pregnancy captured by the DNBC study were 
included in the DWH Study. The DNBC is a prospec-
tive Danish cohort study of 91 827 pregnant women 
enrolled between 1996 and 2002.17 Women with GDM 
were identified from two sources: the Danish National 
Patient Register and/or telephone interviews at 30 weeks 
of gestation or 6 months postpartum.18 Validation using 
hospital records revealed high sensitivity (96%) and spec-
ificity (99%) for GDM diagnoses.18 Characteristics of the 
women who participated in the DWH Study were largely 
comparable with the eligible DNBC women.14 The DNBC 
part of the DWH Study was approved by the Regional 
Scientific Ethical Committee of the Capital Region of 
Denmark (record no. H-4-2013-129). Study procedures 
were followed in accordance with the Declaration of 
Helsinki.
Outcome assessment
In the NHSII, incident T2D was initially identified in the 
biennial questionnaires by women’s reports of physician 
diagnoses and confirmed in a supplementary question-
naire, which included details of the diagnosis. Confirmed 
T2D events were updated through 2017. T2D was defined 
by the National Diabetes Data Group (NDDG) criteria19 
up to 1997. The cut- off for plasma glucose levels was 
lowered for T2D cases identified after 1997 in accor-
dance with the American Diabetes Association (ADA) 
guideline.20 In a previous validation study among a 
similar cohort of US nurses, 98% of the T2D cases identi-
fied using this procedure were confirmed by the medical 
record review performed by an endocrinologist.21
In the DNBC, 607 participants had a clinical examina-
tion including an oral glucose tolerance test (OGTT) 
and biospecimen collection in 2012–2014 (9–16 years 
after the index pregnancy). At the clinical exam, women 
reported physician diagnoses of T2D (WHO recom-
mended the NDDG criteria cutoffs before 1999, and the 
ADA criteria cutoffs after 1999). Incident T2D was also 
identified from the OGTT or HbA1c in accordance with 
the ADA guidelines.20
Covariates assessment
In the NHSII, information on women’s age, smoking 
status, family history of diabetes and self- reported height 
and weight were recorded in the 1989 questionnaire and 
updated in the biennial questionnaires. Body mass index 
(BMI) was calculated from self- reported height and 
weight; self- reported weight was highly correlated with 
weight measured by a technician in a validation study 
(r=0.97).22 Dietary information was collected in 1991 and 
updated every 4 years thereafter using a semiquantitative 
food frequency questionnaire (FFQ) assessing dietary 
intake in the past year. The alternate healthy eating index 
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(AHEI) was derived as the sum of scores of 11 dietary 
components.23 We used the AHEI score derived from the 
earliest dietary assessment after the index pregnancy and 
before T2D diagnosis to reflect dietary quality after the 
index pregnancy.
In the DNBC, information on women’s age, pre- 
pregnancy smoking status, family history of diabetes, and 
self- reported height and weight were recorded in the 
questionnaire administered during the index pregnancy. 
Pre- pregnancy BMI was calculated from self- reported 
height and weight. Dietary information was also collected 
in a questionnaire in the clinical exam using a semiquan-
titative FFQ assessing dietary intake in the past year. The 
AHEI score was derived using similar approach as in the 
NHSII.23
Genotyping
Genotyping was performed using the TaqMan quantita-
tive PCR method (Applied Biosystems, Foster City, CA, 
USA)9 in 1855 DWH Study participants from the NHSII 
and 603 from the DNBC. In all, 112 candidate SNPs were 
selected based on previous genome- wide association 
studies (GWAS) of T2D.9
An additional 208 DWH Study participants from the 
NHSII has genome- wide data from previous nested case–
control studies of kidney stones, ovarian cancer, post- 
traumatic stress disorder, venous thromboembolism, 
endometriosis and breast cancer24 25; none of these condi-
tions have known risk SNPs that overlap with the targeted 
SNPs in the current study. Genotyping was performed 
using high- density SNP markers platforms, including 
Illumina (San Diego, CA, USA), HumanHap, Infinium 
(Natick, MA, USA), OncoArray or Infinium HumanCore-
Exome.9 24–26 Genotypes were imputed with the Michigan 
Server27 using the 1000 Genomes Project ALL Phase I 
Integrated Release v3 haplotypes.28 Accurate genotype 
results were obtained for most SNPs, as measured by 
a sample call rate of 97% or a high imputation quality 
score (r2 ≥0.8) estimated using the MACH software 
(Cincinnati, OH, USA). The minor allele frequency and 
the imputation quality scores of all genotyped SNPs were 
similar across different platforms.9
GRs of T2d
In all, 78 out of the 112 T2D SNPs were identified in the 
European populations based on information obtained 
from the recent GWAS catalog (https://www. ebi. ac. uk/ 
gwas/). After excluding 18 SNPs in high linkage disequi-
librium and one SNP (HLA- B, rs2244020) with low geno-
typing call rate, 59 SNPs were retained. An unweighted 
GRS was constructed as the sum of the number of T2D 
risk alleles (ie, 0, 1, 2) across the 59 T2D SNPs, assuming 
an additive genetic model and that each SNP contributed 
to the disease risk equally and independently. We did not 
construct a weighted GRS as weights for the T2D SNPs 
are not available among women with a history of GDM. 
Furthermore, unweighted GRS has been shown to be 
more robust to errors arising from differences in effect 
size and population structure.29 GRS for participants 
with missing genotype data were standardized to those 
with complete genotype data (standardized GRS = [total 
number of risk alleles/number of non- missing genotype 
×2]×59), as previously described.30
Among all DWH Study participants with genetic data 
(n=2063 from the NHSII; n=603 from the DNBC), self- 
reported non- white women (n=77) in the NHSII were 
excluded to minimize population stratification; all DNBC 
participants were self- reported white. Participants with 
poor sample quality9 (ie, where genotyping failed for >53 
SNPs) were also excluded (n=102 in the NHSII and n=53 
in DNBC). As a result, the final analytic sample included 
1884 participants from the NHSII and 550 from the 
DNBC. Individuals in the final analytic sample have an 
average genotyping rate of 97% in the NHSII and 98% in 
the DNBC across the 59 SNPs.
statistical analysis
The association of the GRS with the risk of T2D was 
estimated separately in the NHSII and DNBC using log- 
binomial models, adjusting for women’s year of birth. The 
results of the two cohorts were meta- analyzed using fixed 
effects models weighted by inverse variance of the esti-
mates; no significant heterogeneity between the results 
from the two cohorts was observed (all p values for Q- sta-
tistic ≥0.05, I2 was 0%–42%). We estimated the relative 
risks (RRs) of T2D by quartiles of the GRS and tested for 
a linear trend of the association over increasing quartiles 
using the median GRS value of each quartile. We also esti-
mated the per five allele RR using the GRS as a contin-
uous variable. To provide insights into the specific SNPs 
contributing to the GRS- T2D associations, we examined 
individual SNPs in relation to T2D risk and estimated the 
RRs for each additional copy of the risk allele, assuming 
an additive genetic model. Both the original p value and 
the p value corrected for false discovery rate (FDR) were 
presented for the pool results.
To test the robustness of our findings to SNP selec-
tion criteria, we conducted a sensitivity analysis using an 
alternative GRS based on 42 of the 59 SNPs confirmed to 
be T2D risk SNPs in recent GWAS meta- analysis among 
European populations.31 32 To explore biological path-
ways of the potential genetic effects, we also constructed 
additional GRSs based on a subset of 34 SNPs postulated 
to be related to beta cell function (GRSBC) and a subset 
of 11 SNPs postulated to be related to insulin resistance 
(GRSIR).
33 34 To investigate whether the GRS- T2D associa-
tion was modified by non- genetic risk factors of T2D, we 
stratified the main analysis in each cohort by women’s 
age at GDM diagnosis (≤35,>35 years), pre- pregnancy 
BMI (<25, 25–29,≥30 kg/m2), family history of diabetes 
(yes, no), dietary quality after the index pregnancy 
(AHEI <median, ≥median) and physical activity after the 
index pregnancy. Interactions were tested using a multi-
plicative term between the GRS as a continuous variable 
and each potential effect modifier. All statistical analyses 
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Table 1 Characteristics of study participants among 
women with a history of gestational diabetes in the NHSII 
and the DNBC
Characteristics
NHSII 
(n=1884)
DNBC 
(n=550)
Type 2 diabetes cases, n (%) 446 (23.7) 155 (28.2)
Length of follow- up (years), 
mean±SD
21.3±5.6 12.7±1.5
Age at the index pregnancy 
(years), mean±SD
30.5±5.3 31.7±4.6
Age at the last follow- up* (years), 
mean±SD
56.0±6.3 43.8±4.7
Family history of diabetes at the 
index pregnancy†, n (%)
472 (28.6) 204 (37.1)
Pre- pregnancy smoking, n (%) 55 (8.4%) 145 (26.4)
Pre- pregnancy BMI, n (%)
  <25 kg/m2 335 (51.2) 209 (38.0)
  25–29 kg/m2 171 (26.2) 149 (27.1)
  ≥30 kg/m2 148 (22.6) 150 (27.3)
*In the NHSII, the last follow- up was the date of last questionnaire 
return, date of death or date of type 2 diabetes cases, whichever 
occurred earliest; in DNBC, the last follow- up was the follow- up 
clinical exam.
†In the NHSII, for women who reported GDM before 1989, it refers 
to characteristics at 1989.
BMI, body mass index; DNBC, Danish National Birth Cohort; 
NHSII, Nurses’ Health Study II.
were performed using SAS (V.9.4, SAS Institute, Cary, 
NC, USA).
ResulTs
The characteristics of the study participants in the 
NHSII and the DNBC are presented in table 1. Women 
on average were followed for 21.3 years (SD=5.6) in the 
NHSII and 12.7 years (SD=1.5) in the DNBC after the 
index pregnancy. During the follow- up period, a total of 
601 women developed T2D: 446 (23.7%) in the NHSII 
and 155 (28.2%) in the DNBC. Women in the NHSII 
were of a similar age at the index pregnancy but older at 
the last follow- up compared with women in the DNBC. 
Women in the NHSII were also less likely to have a family 
history of diabetes, less likely to smoke, and leaner than 
women in the DNBC.
Cutpoints for the quartiles of GRS in the study popu-
lation were 64.0, 68.0 and 72.0 in NHSII and 63.1, 67.7 
and 71.0 in DNBC, which were slightly higher than in 
the entire background population of the respective 
cohorts (63.6, 67.2 and 71.0 in NHSII; 63.0, 66.1 and 
70.0 in DNBC; data not shown). Median AHEI after the 
index pregnancy in the study population was 46.5 (IQR: 
39.5–54.0) in NHSII and 51.9 (IQR: 45.2–58.4) in DNBC. 
In NHSII, median AHEI at the first dietary assessment 
in 1991 was slightly lower in the study population (46.5, 
IQR: 39.5–54.0) than in the entire background popu-
lation of NHSII (47.5, IQR: 40.0–55.0). Distributions 
of GRS, BMI and AHEI by T2D status are presented in 
online supplementary table S1.
The GRS was positively associated with the risk of devel-
oping T2D. In the pooled analysis, the RRs (95% CI) of 
T2D for increasing quartiles of the GRS were 1.00 (ref), 
0.97 (0.79 to 1.21), 1.25 (1.03 to 1.52) and 1.19 (0.97 to 
1.45) (p trend=0.02). Every five risk alleles increase in 
the GRS was associated with a 7% (95% CI: 1.01 to 1.14) 
increased risk of T2D (p=0.02) (table 2). Associations 
were in general similar in the cohort- specific analyses. 
Each five alleles increase in the GRS was associated with 
a 7% (95% CI: 1.00 to 1.15) increased risk of T2D in the 
NHSII and a 9% (95% CI: 0.96 to 1.23) increased risk of 
T2D in the DNBC (table 2).
In total, 11 individual SNPs were nominally signifi-
cantly (p≤0.05) associated with the risk of T2D in the 
pooled analysis, although none of the associations was 
significant after FDR correction (see online supplemen-
tary table S2 and figure S1). Specifically, eight SNPs 
(KCNQ1 [rs231356], AP3S2 [rs2028299], ARF5/PAX4/
SND1 [rs10229583], WFS1 [rs1801214, rs4689388], 
GPSM1 [rs11787792], HNF1B [rs4430796] and CDKAL1 
[rs7766070]) were positively associated with T2D risk, 
whereas three SNPs (CDKN2A/B [rs10811661, rs7020996] 
and GLIS3 [rs7041847]) were inversely associated with 
the risk of T2D. In sensitivity analysis repeating the main 
analysis recoding the alternative alleles in CDKN2A/B 
[rs10811661, rs7020996] and GLIS3 [rs7041847] as the 
risk alleles, the RRs of T2D across increasing quartiles of 
the GRS became monotonic (data not shown).
The alternative GRS constructed based on 42 SNPs 
yielded similar results. The pooled RRs (95% CI) for 
increasing quartiles of the GRS were 1.00 (ref), 1.15 (0.94 
to 1.42), 1.15 (0.94 to 1.41) and 1.26 (1.03 to 1.54) (p 
trend=0.03). Higher GRSIR, but not GRSBC, was signifi-
cantly associated with increased T2D risk in NHSII; the 
RRs for increasing quartiles of GRSIR 1.00 (ref), 1.47 
(1.14 to 1.89), 1.48 (1.18 to 1.85) and 1.34 (1.05 to 1.71), 
respectively (p trend=0.01). However, such findings were 
not observed in the DNBC (online supplementary table 
S3).
Although tests of interactions were not statistically 
significant, the association of GRS with T2D appeared 
stronger among women with poorer dietary quality after 
the index pregnancy (AHEI <median) than those with 
better dietary quality (AHEI ≥median) (figure 1). Similar 
patterns were observed in both cohorts. In the NHSII, 
among women with poorer dietary quality, the RRs of 
T2D across increasing quartiles of the GRS were 1.00, 
0.99, 1.51 and 1.29 (p trend=0.06), and the RR for every 
five risk alleles increase in the GRS was 1.13 (95% CI: 
1.00 to 1.27), whereas among women with better dietary 
quality, RR across increasing quartiles of the GRS were 
1.00, 0.83, 0.81 and 0.94 (p trend=0.79), and the RR for 
every five risk alleles increase in the GRS was 0.97 (95% 
CI: 0.85 to 1.11) (p interaction=0.11). In the DNBC, 
among women with poorer dietary quality, the RRs of 
T2D across increasing quartiles of the GRS were 1.00 
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(ref), 1.58, 1.86 and 1.42 (p trend=0.18), and the RR for 
every five risk alleles increase in the GRS was 1.10 (95% 
CI: 0.94 to 1.28), whereas, among women with better 
dietary quality, and RR across increasing quartiles of the 
GRS were 1.00 (ref), 0.50, 1.21 and 0.96 (p trend=0.68), 
and the RR for every five risk alleles increase in the GRS 
was 1.05 (95% CI: 0.86 to 1.30) (p interaction=0.75). The 
association of GRS with T2D risk did not differ materially 
by other risk factors of T2D including age at the index 
pregnancy, pre- pregnancy BMI, family history of diabetes 
and physical activity after the index pregnancy.
dIsCussIOn
In the present study, based on two independent popula-
tions with a long follow- up of white women with a history 
of GDM, a higher GRS was significantly associated with a 
higher risk of T2D, and the findings were largely consis-
tent across the two populations in the USA and Denmark. 
We also found suggestive evidence that the association 
may be modified by dietary quality after the index preg-
nancy; the association was stronger among women with 
poorer dietary quality after the index pregnancy than 
among women with a better dietary quality.
Although women with a history of GDM have a greatly 
increased risk for T2D, not all develop T2D. Few studies 
have examined genetic factors of T2D in this high- risk 
population.10–13 A higher GRS for T2D was significantly 
associated with a higher risk of T2D in several studies of 
women with a history of GDM.10–12 However, inferences 
from these studies are hindered by small numbers of T2D 
cases (n<150), and relatively short follow- up periods (<5 
years). In addition, among a subgroup of 218 women 
in the Diabetes Prevention Programme (DPP) diag-
nosed with GDM 12 years earlier, a higher GRS for T2D 
was marginally associated with a greater T2D risk (HR: 
1.04; 95% CI: 1.00 to 1.08).13 Of note, some studies used 
weighted GRS where the weights were derived using the 
same study population,11 12 raising concerns for model 
overfitting.35 Given the differences in GRS construction, 
the number of SNPs included to construct the GRS and 
the characteristics of the study populations, comparison of 
results across these studies is challenging. One important 
contribution of the present study is that a much larger 
sample of women with a history of GDM (2428 women 
with a history of GDM, of which 600 developed T2D) 
were followed for a minimum of 9 years (mean 21 years 
in the NHSII and 13 years in DNBC), providing more 
complete outcome adjudication.
Our estimate of RR of T2D associated with every five 
alleles increase in the GRS among women with a history 
of GDM was slightly weaker than that in the general 
population.7 As most of the GDM risk SNPs identified in 
GWAS were also associated with T2D risk,8 36 the smaller 
effect size among women with GDM likely reflects an 
already higher baseline genetic risk for T2D than the 
general population, as we have demonstrated.
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Figure 1 Relative risks and 95% CIsa of T2D associated with the GRSs for T2D among women with a history of GDM in the 
NHSII (n=1206) and the DNBC (n=538), stratified by AHEI above and below median after pregnancy. aEstimated in log- binomial 
models adjusting for women’s year of birth. bAHEI was derived from the earliest dietary assessment after the index pregnancy; 
included 588 women with AHEI score below median and 618 women with AHEI scores above median. cAHEI was derived from 
the dietary assessment at the follow- up clinical exam; included 269 women with AHEI score below median and 269 women 
AHEI score above median. Q1—first quartile; Q2—second quartile; Q3—third quartile; Q4—fourth quartile. AHEI, alternate 
healthy eating index; DNBC, Danish National Birth Cohort; GDM, gestational diabetes mellitus; GRS, genetic risk scores; 
NHSII, Nurses’ Health Study II; T2D, type 2 diabetes
Among the SNPs included in the GRS, eight SNPs 
showed nominally significant (p≤0.05) positive associ-
ations with T2D risk, although none of the associations 
was significant after FDR correction. Interestingly, only 
one of the SNPs—CDKAL1 (rs7766070)—is among the 
10 SNPs with the strongest association with T2D risk in 
the general population31 (all 10 SNPs or their proxies 
were included in this study). Most of the eight SNPs are 
related to beta- cell function.33 34 On the other hand, three 
SNPs (CDKN2A/B [rs10811661, rs7020996] and GLIS3 
[rs7041847]) showed significantly inverse associations 
with T2D risk, and the direction was consistent across the 
two cohorts. CDKN2A/B (rs7020996) was not confirmed 
as a T2D SNP in the recent GWAS meta- analyses in the 
general population.31 37 Whereas evidence supporting 
the T allele of CDKN2A/B (rs10811661)31 38 and the A 
allele of GLIS3 (rs7041847)37 as T2D risk alleles in the 
general population is strong; both SNPs are implicated 
in beta- cell function.33 34 Our sensitivity analyses showed 
that the inverse association of the three SNPs with T2D 
risk accounted for the non- monotonic appearance of 
RRs of T2D across the GRS quartiles. To our knowledge, 
this is the first study examining a set of candidate SNPs 
in relation to the risk of T2D in women with a history 
of GDM. Future studies of larger size are needed, which 
may require consortium efforts.
Of note, we observed suggestive evidence that the GRS- 
T2D association was potentially modified by women’s 
dietary quality. The association appeared stronger among 
women with a poor dietary quality after pregnancy than 
among women with a better one. Although the inter-
action was not significant, the findings were consistent 
in both cohorts. We are unaware of previous studies on 
gene- lifestyle interactions and the risk of T2D among 
women with a history of GDM. These findings were in 
parallel to those reported in several studies in general 
population. For instance, in the DPP, intensive lifestyle 
interventions mitigated the excess T2D risk associated 
with a higher GRS for T2D.39 Furthermore, in both DPP40 
and the Finnish Diabetes Prevention Study,41 intensive 
lifestyle interventions also mitigated the excess T2D risk 
associated with polymorphisms in TCF7L2—a leading 
T2D risk loci in general population. Our findings suggest 
that even among women at substantially high risk, that is, 
women with a history of GDM, a healthier diet may help 
to mitigate the excess genetic risk of T2D.
This study has several unique strengths. First, this 
is the largest study on GRS and the risk of developing 
T2D among women with a history of GDM,11 conferring 
stronger statistical power than previous studies. Second, 
including two independent populations increased the 
robustness of our findings. Third, the DWH Study and 
the constituting cohorts collected extensive data on non- 
genetic risk factors of T2D, which allowed us to examine 
potential effect modification by non- genetic risk factors 
of T2D—the first of such investigations among women 
with a family history of GDM. Lastly, the long study 
follow- up, an average of 21 years in the NHSII and 13 
years in DNBC, presumably allowed us to capture a larger 
proportion of women who would eventually develop 
T2D. In comparison, existing studies either had less than 
5 years of follow- up after the GDM pregnancy10–12 or 
missed T2D cases which occurred within the first decade 
after the GDM pregnancy.13
Our study also has a few potential limitations. First, 
because our T2D SNPs were selected and genotyped 
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a few years ago using the best evidence present at that 
time, our GRS may not capture all the SNPs confirmed 
in the most recent GWAS meta- analysis.31 However, 42 
out of the 59 SNPs were either directly confirmed in 
the more recent GWAS meta- analyses31 37 or are strongly 
linked with a confirmed SNP. Sensitivity analysis using a 
GRS including these 42 SNPs yielded similar results as 
the GRS including the 59 SNPs. Second, despite being 
the largest genetic study by far on T2D among women 
with GDM, our study may be not sufficiently powered to 
examine the associations of individual T2D SNPs in rela-
tion to the risk of developing T2D. Third, due to lack 
of information on the date of GDM or T2D diagnosis in 
a fraction of our sample, we were not able to perform 
time- to- event analysis. Among women with data on time 
to event available, adjustment for duration of follow- up 
did not alter the association between the GRS and T2D 
risk in either cohort. In addition, in DNBC, dietary data 
were collected only once at a clinical exam 9–16 years 
after the index pregnancy, which may not necessarily 
reflect habitual diet from the index pregnancy to T2D. 
Lastly, the generalizability of our findings to non- white 
populations warrants further investigation. However, the 
homogeneity of our population minimized potential bias 
due to population stratification.
COnClusIOns
In this study based on two independent populations with 
a long follow- up period, we observed a significant associa-
tion of genetic risk factors with the development of T2D. 
The magnitude of association, however, was modest. 
There was also suggestive evidence that a healthful 
dietary pattern might mitigate the excessive risk of T2D 
related to greater genetic susceptibility, which supports 
public health efforts of encouraging a healthful diet to 
prevent T2D among the high- risk population—women 
with a history of GDM.
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